06:47:51 Europe / Stockholm

Attachments

Share price & Turnover

Share price change and turnover during the day of this press release

Calendar

2025-02-20 Year-end Report 2024
2024-11-21 Quarterly Report 2024-Q3
2024-08-22 Quarterly Report 2024-Q2
2024-05-24 Ex-date Ordinary Dividend DIGN 0.00 SEK
2024-05-23 Annual General meeting
2024-05-23 Quarterly Report 2024-Q1
2024-03-12 Extra General Meeting 2024
2024-02-15 Year-end Report 2023
2023-11-16 Quarterly Report 2023-Q3
2023-08-17 Quarterly Report 2023-Q2
2023-05-26 Ex-date Ordinary Dividend DIGN 0.00 SEK
2023-05-25 Quarterly Report 2023-Q1
2023-05-25 Annual General meeting
2023-02-16 Year-end Report 2022
2022-11-17 Quarterly Report 2022-Q3
2022-08-18 Quarterly Report 2022-Q2
2022-05-20 Ex-date Ordinary Dividend DIGN 0.00 SEK
2022-05-19 Annual General meeting
2022-05-19 Quarterly Report 2022-Q1
2022-02-17 Year-end Report 2021
2021-11-18 Quarterly Report 2021-Q3
2021-08-19 Quarterly Report 2021-Q2
2021-05-21 Ex-date Ordinary Dividend DIGN 0.00 SEK
2021-05-20 Annual General meeting
2021-05-20 Quarterly Report 2021-Q1
2021-02-18 Year-end Report 2020
2021-01-11 Extra General Meeting 2021
2020-11-19 Quarterly Report 2020-Q3
2020-08-20 Quarterly Report 2020-Q2
2020-06-26 Ex-date Ordinary Dividend DIGN 0.00 SEK
2020-06-25 Annual General meeting
2020-05-28 Quarterly Report 2020-Q1
2020-02-25 Year-end Report 2019
2020-02-10 Extra General Meeting 2019
2019-11-19 Quarterly Report 2019-Q3
2019-08-22 Quarterly Report 2019-Q2
2019-05-16 Ex-date Ordinary Dividend DIGN 0.00 SEK
2019-05-16 Quarterly Report 2019-Q1
2019-05-15 Annual General meeting
2019-02-26 Year-end Report 2018
2018-11-27 Quarterly Report 2018-Q3
2018-08-21 Quarterly Report 2018-Q2
2018-05-22 Quarterly Report 2018-Q1
2018-04-27 Ex-date Ordinary Dividend DIGN 0.00 SEK
2018-04-26 Annual General meeting
2018-02-22 Year-end Report 2017
2017-12-04 Extra General Meeting 2017
2017-11-23 Quarterly Report 2017-Q3
2017-08-24 Quarterly Report 2017-Q2
2017-06-02 Annual General meeting
2017-05-24 Quarterly Report 2017-Q1
2017-02-23 Year-end Report 2016
2016-11-24 Quarterly Report 2016-Q3
2016-08-25 Quarterly Report 2016-Q2
2016-05-25 Quarterly Report 2016-Q1
2016-03-23 Ex-date Ordinary Dividend DIGN 0.00 SEK
2016-03-22 Annual General meeting
2016-02-24 Year-end Report 2015
2015-11-25 Quarterly Report 2015-Q3
2015-08-26 Quarterly Report 2015-Q2
2015-05-27 Quarterly Report 2015-Q1
2015-05-19 Ex-date Ordinary Dividend DIGN 0.00 SEK
2015-02-24 Year-end Report 2014
2014-11-25 Quarterly Report 2014-Q3
2014-08-26 Quarterly Report 2014-Q2
2014-05-20 Quarterly Report 2014-Q1
2014-05-19 Ex-date Ordinary Dividend DIGN 0.00 SEK
2014-05-16 Annual General meeting
2014-03-04 Extra General Meeting 2014
2014-02-27 Year-end Report 2013
2013-11-28 Quarterly Report 2013-Q3
2013-08-28 Quarterly Report 2013-Q2
2013-08-28 Extra General Meeting 2013
2013-05-22 Quarterly Report 2013-Q1
2013-05-22 Ex-date Ordinary Dividend DIGN 0.00 SEK
2013-05-21 Annual General meeting
2013-02-27 Year-end Report 2012
2012-11-28 Quarterly Report 2012-Q3
2012-10-30 Extra General Meeting 2012
2012-09-28 Capital Market Day 2012
2012-08-28 Quarterly Report 2012-Q2
2012-06-29 Annual General meeting
2012-05-28 Quarterly Report 2012-Q1
2012-02-27 Year-end Report 2011
2011-11-17 Quarterly Report 2011-Q3
2011-08-22 Quarterly Report 2011-Q2
2011-06-13 Ex-date Ordinary Dividend DIGN 0.00 SEK
2011-06-10 Annual General meeting
2011-05-30 Quarterly Report 2011-Q1
2011-02-25 Year-end Report 2010
2010-11-18 Quarterly Report 2010-Q3
2010-08-19 Quarterly Report 2010-Q2
2010-06-21 Ex-date Ordinary Dividend DIGN 0.00 SEK
2010-05-18 Quarterly Report 2010-Q1
2010-02-18 Year-end Report 2009
2009-12-21 Split DIGN 100:1
2009-11-18 Quarterly Report 2009-Q3

Description

CountrySweden
ListFirst North Stockholm
SectorHealth care
IndustryMedical technology
Dignitana är verksamt inom medicinteknik. Bolaget utvecklar, tillverkar och marknadsför medicinska hjälpmedel som primärt används som skalpkylningssystem vid cytostatikabehandling, vars syfte är att eliminera eller kraftigt reducera håravfall. Bolaget har global verksamhet främst inom Norden, Europa, Nordamerika och Asien. Dignitana grundades år 2007 och har sitt huvudkontor i Lund.
2023-08-17 07:00:00

Dignitana AB (http://www.dignitana.se/), manufacturer of The DigniCap® Scalp Cooling System, has expanded the agreement with oneservice (https://one-service.com/), to provide service and maintenance to European health care facilities offering the DigniCap Delta model of the DigniCap Scalp Cooling System.

As part of Dignitana's ongoing commitment to high-quality customer service, DigniCap Delta customers in Europe can now access the extensive oneservice network for installation, maintenance, technical support and repairs. oneservice, a global provider of specialty technical services, has worked with Dignitana since 2019, previously focusing their efforts on the legacy C3 device.  With the introduction of the DigniCap Delta model to Europe, health care providers in Italy, Germany, Spain, Sweden, and The United Kingdom are now utilizing the next generation in scalp cooling technology that is offered with the DigniCap Delta model. As initial warranties expire, these customers can purchase Service Level Agreements from Dignitana which will be administered by oneservice.

"The ability to offer service in the field means European customers now have access to rapid-response service with a high-level of expertise," said Catarina Löwenadler, CEO of Dignitana.  "As we work to efficiently to expand DigniCap availability, we know we can rely on the industry experts and state-of-the-art resources at oneservice for consistent, high-quality and excellent service."

"We are proud to expand the scope of our work with Dignitana, servicing a market with enormous potential, while also supporting quality of life for cancer patients," said Matthias Raquet, CEO of oneservice. "We enjoy working with new technologies such as the thermoelectric cooling system in DigniCap Delta that can positively impact the quality of life of patients undergoing chemotherapy and we look forward seeing more customers across Europe adopt this innovative technology."

Löwenadler added, "Excellent customer service is a top priority for Dignitana, where we see 94 percent of DigniCap patients surveyed state they would recommend DigniCap to others, and 75 percent report satisfaction with their DigniCap results.  With this expanded oneservice agreement, we continue to do all we can to support the patient's journey with dignity and respect."

Hailed internationally as a life-changing medical advancement for cancer patients, The DigniCap Scalp Cooling System was invented by a Swedish Oncology nurse in 1999 and has been available in Europe since 2001. DigniCap was the first scalp cooling system to be cleared by the US Food and Drug Administration and is used to minimize chemotherapy induced hair loss in patients with solid tumor cancers. The pivotal trial achieved clinically superior results, with 66.3 percent of patients keeping the majority of their hair while undergoing chemotherapy.

There are nearly 3.7 million new cancer diagnoses in Europe per year (WHO (http://www.euro.who.int/en/health-topics/noncommunicable-diseases/cancer/data-and-statistics)) and breast cancer is the most common cancer in European women with approximately 500,000 new diagnoses per year (European Breast Cancer Coalition (https://www.europadonna.org/breast-cancer-facs/)).